Ongoing Disclosure Notice

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
15 September 2020
Date of last disclosure:
8 July 2020
Director or senior manager giving disclosure
Full name(s):
Andrew Robert Donald Somervell
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Not Applicable
Position held in listed issuer:
Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Cancellation of Options and issue of Ordinary Shares
(b) Issue and Exercise of Performance Share Rights
(c) Sale of Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial
For that relevant interest
Number held in class before acquisition or disposal:
(a) 128,823 Options
(b) 42,631 PSRs
(c) 71,044 Ordinary Shares
Number held in class after acquisition or disposal:
(a) 88,672 Options
(b) 28,275 PSRs
(c) 80,779 Ordinary Shares
Current registered holder(s):
Andrew Robert Donald Somervell
Registered holder(s) once transfers are registered:
Andrew Robert Donald Somervell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Two
Details of transactions requiring disclosure-
Date of transaction:
(a) 4 & 14 September
(b) 4 & 10 September
(c) 11 & 14 September
Nature of transaction:
(a) Issue of Options; cancellaton of Options and issue of
Ordinary Shares
(b) Issue of PSRs; exercise of PSRs and issue of Ordinary
Shares
(c) Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily converted into a
cash value, describe the consideration:
(a) $nil
(b) $nil
(c) $1,721,271.31
Number of financial products to which the transaction related:
(a) Issue of 20,090 Options; cancellation of 60,241 Options
and issue of 41,007 Ordinary Shares;
(b) Issue of 6,372 PSRs; exercise of 20,728 PSRs and issue
of 20,728 Ordinary Shares
(c) 52,000 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the aquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:15 September 2020
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
15 September 2020
Date of last disclosure:
17 July 2020
Director or senior manager giving disclosure
Full name(s):Paul Nigel Shearer
Name of listed issuer:Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Senior Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial
For that relevant interest-
Number held in class before acquisition or disposal:
(a) 180,853 Options
(b) 78,983 PSRs
(c) 356,661 Ordinary Shares
Number held in class after acquisition or disposal:
(a) 155,928 Options
(b) 49,729 PSRs
(c) 396,460 Ordinary Shares
Current registered holder(s):Paul Nigel Shearer and Shearer Family Trust
Registered holder(s) once transfers are registered:Paul Nigel Shearer and Shearer Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Three
Details of transactions requiring disclosure-
Date of transaction:
(a) 4 & 8 September
(b) 4 & 9 September
(c) 9 & 10 September
Nature of transaction:
(a) Issue of Options; cancellaton of Options and issue of
Ordinary Shares
(b) Issue of PSRs; exercise of PSRs and issue of Ordinary
Shares
(c) Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
(a) $nil
(b) $nil
(c) $1,322,842.69

Number of financial products to which the transaction related:
(a) Issue of 34,364 Options; cancellation of 59,289 Options
and issue of 39,146 Ordinary Shares
(b) Issue of 10,899 PSRs; exercise of 40,153 PSRs and
issue of 40,153 Ordinary Shares
(c) 39,500 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the aquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:15 September 2020
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person: